When was NucsAI founded?

NucsAI was founded in 2024 and raised its 1st funding round within a year of its incorporation.

Where is NucsAI located?

NucsAI is headquartered in Dover, United States.

Who is the current CEO of NucsAI?

Nijat Ahmadov of NucsAI. They have also founded 1 company.

Is NucsAI a funded company?

NucsAI is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 20, 2024.

When was the latest funding round of NucsAI?

NucsAI's latest funding was a $***** Seed round on Aug 20, 2024, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.43B in funding in 2026 to date.

Where does NucsAI rank among its competitors?

NucsAI ranks 186th amongst 1162 active competitors, of which 332 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of NucsAI?

NucsAI's top competitors include Natera, Guardant Health and PAIGE. Among them, Guardant Health secured the most recent funding round in November, 2025.

NucsAI - 2026 Company Profile, Team, Funding & Competitors

Company Details

AI-powered healthcare platform for advanced analysis of tumor lesions. The company's products include DeepPSMA fast and reproducible whole-body tumor burden quantification in CT imaging for patients with prostate cancer and SelectPSMA for the prediction of patient outcome after treatment with PSMA-targeted radiopharmaceuticals.

Key Metrics

Founded Year

2024

Location

Dover, United States

Stage

Seed

Total Funding

$3.5M in 1 round

Latest Funding Round

Seed, Aug 20, 2024, $*****

Ranked

186^th among 1162 active competitors

Similar Companies

PAIGE & 303 more

View NucsAI's full profile

NucsAI is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
NUCS AI INC CIN: 3278370 , United States, Active	Mar 15, 2024	-	-	-

NucsAI has raised a total funding of $3.5M over 1 round.

Here is the list of recent funding rounds of NucsAI:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 20, 2024	3113444	Seed	3924433	5908215	1120194	3585916

Access funding benchmarks and valuations. Sign up today!

View details of NucsAI's funding rounds and investors

The founders of NucsAI is Nijat Ahmadov. Nijat Ahmadov is the CEO of NucsAI.

Here are the details of NucsAI's key team members:

Nijat Ahmadov: Co-Founder & CEO of NucsAI.
Contact Info: 1 email address

View details of NucsAI's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NucsAI include Natera, Guardant Health and PAIGE. Here is the list of Top 10 competitors of NucsAI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 18 others	77/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Sequoia Capital, SoftBank Vision Fund & 25 others	75/100
3rd	PAIGE 2018, New York City (United States), Acquired	Developer of AI applications and foundation models for cancer diagnostics	$241M	Goldman Sachs, Casdin Capital & 9 others	71/100
4th	Lunit 2013, Seoul (South Korea), Public	Developer of medical software for cancer screening and oncology diagnostics	$135M	InterVest, Shinhan Investment Corp & 25 others	71/100
5th	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, Tiger Global Management ... & 22 others	71/100
6th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Ibex 2016, Tel Aviv (Israel), Series C	Provider of AI-powered diagnostic solutions for pathology	$114M	83NORTH, Kreos Capital & 6 others	68/100
10th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
186th	NucsAI 2024, Dover (United States), Seed	AI-powered healthcare platform for advanced analysis of tumor lesions	$3.5M	-	44/100